28328-53-2

Basic information

• Product Name: BUMETANIDE RELATED COMPOUND B (25 MG) (3-NITRO-4-PHENOXY-5-SULFAMOYLBENZOIC ACID)
• Synonyms: BUMETANIDE RELATED COMPOUND B (25 MG) (3-NITRO-4-PHENOXY-5-SULFAMOYLBENZOIC ACID);3-nitro-4-phenoxy-5-sulphamoylbenzoic acid;3-Nitro-4-phenoxy-5-sulfamoylbenzoic acid;BuMetanide iMpurity (3-Nitro-4-phenoxy-5-sulfaMoylbenzoic Acid);BuMetanide Related CoMpound B
• CAS NO: 28328-53-2
• Molecular Formula: C₁₃H₁₀N₂O₇S
• Molecular Weight: 338.2927
• EINECS: 248-970-6
• Product Categories: Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds
• Mol File: 28328-53-2.mol
• Article Data: 7

Chemical Properties

• Melting Point: 251-253°C (dec.)
• Boiling Point: 547.6 °C at 760 mmHg
• Flash Point: 285 °C
• Appearance: /
• Density: 1.585g/cm³
• Vapor Pressure: 7.95E-13mmHg at 25°C
• Refractive Index: 1.651
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 3.13±0.10(Predicted)
• CAS DataBase Reference: BUMETANIDE RELATED COMPOUND B (25 MG) (3-NITRO-4-PHENOXY-5-SULFAMOYLBENZOIC ACID)(CAS DataBase Reference)
• NIST Chemistry Reference: BUMETANIDE RELATED COMPOUND B (25 MG) (3-NITRO-4-PHENOXY-5-SULFAMOYLBENZOIC ACID)(28328-53-2)
• EPA Substance Registry System: BUMETANIDE RELATED COMPOUND B (25 MG) (3-NITRO-4-PHENOXY-5-SULFAMOYLBENZOIC ACID)(28328-53-2)

Safety Data

• Hazardous Substances Data: 28328-53-2(Hazardous Substances Data)

Usage

Chemical Properties

Yellow Solid

Uses

3-Nitro-4-phenoxy-5-sulfamoylbenzoic Acid is a compound related to Piretanide (P508700) and an intermediate in the production of Bumetanide, Bumetanide Impurity A (B689550).

InChI:InChI=1/C13H10N2O7S/c14-23(20,21)11-7-8(13(16)17)6-10(15(18)19)12(11)22-9-4-2-1-3-5-9/h1-7H,(H,16,17)(H2,14,20,21)

Upstream product

• 22892-96-2 4-chloro-3-nitro-5-sulfamoylbenzoic acid 
• 108-95-2 phenol 
• 60376-73-0 3-(dimethylaminomethylenesulfamoyl)-5-nitro-4-phenoxybenzoic acid methyl ester 
• 61658-43-3 3-nitro-4-phenoxy-5-sulfamoyl-benzoic acid sodium salt 

Downstream Products

• 1411657-14-1 3-(di(butyl-d9)amino)-4-phenoxy-5-sulfamoylbenzoic acid 
• 1411657-52-7 methyl 3-(di(butyl-d9)amino)-4-phenoxy-5-sulfamoylbenzoate 
• 57939-04-5 3-nitro-4-phenoxy-5-sulfamoylbenzoic acid methyl ester 
• 57939-09-0 4-phenoxy-3-(piperidin-1-yl)-5-sulfamoylbenzoic acid 
• 1431505-42-8 methyl 3-(N-((dimethylamino)methylene)sulfamoyl)-4-phenoxy-5-(piperidin-1-yl)benzoate 
• 1431501-29-9 C₂₂H₂₈N₂O₅S 
• 1357459-06-3 3-(heptan-4-ylamino)-4-phenoxy-5-sulfamoyl-benzoic acid 
• 1357458-81-1 3-dipentylamino-4-phenoxy-5-sulfamoyl-benzoic acid 
• 1357465-05-4 3-(dimethylaminomethylene-sulfamoyl)-5-dipentylamino-4-phenoxy-benzoic acid methyl ester 
• 1357458-70-8 3-(bis(cyclopropylmethyl)amino)-4-phenoxy-5-sulfamoylbenzoic acid 
• 60376-73-0 3-(dimethylaminomethylenesulfamoyl)-5-nitro-4-phenoxybenzoic acid methyl ester 
• 60376-74-1 5-amino-3-(dimethylaminomethylenesulfamoyl)-4-phenoxybenzoic acid methyl ester 
• 28328-54-3 3-amino-5-(aminosulfonyl)-4-phenoxybenzoic acid 
• 28395-01-9 5-acetylsulphamyl-3-nitro-4-phenoxy-benzoic acid 

Relevant articles and documents

Discovery of a Small Molecule Drug Candidate for Selective NKCC1 Inhibition in Brain Disorders

-

2,3,5 TRISUBSTITUTED ARYL AND HETEROARYL AMINO DERIVATIVES, COMPOSITIONS, AND METHODS OF USE

Compounds are disclosed that have a formula represented by the following:(I) wherein Cy, L1 R1, R2a, R2b, R3, R4, n, and L2 are as described herein. These compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example addictive disorders, Alzheimer's Disease, anxiety disorders, ascites, autism, bipolar disorder, cancer, depression, endothelial corneal dystrophy, edema, epilepsy, glaucoma, Huntington's Disease, inflammatory pain, insomnia, ischemia, migraine, migraine with aura, migraine without aura, neuropathic pain, nociceptive neuralgia, nociceptive pain, ocular diseases, pain, itch, excessive itch, Pruritis, neuropathic pruritis, Parkinson's disease, personality disorders, postherpetic neuralgia, psychosis, schizophrenia, seizure disorders, tinnitus, and withdrawal syndromes.

SUBSTITUTED ANTHRANILIC ACIDS

Disclosed herein are substituted anthranilic acids, pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and medical use of such compounds for the treatment and/or management of hypertension, edema associated with congestive heart failure, hepatic disease, renal disease including nephrotic syndrome, or clearance of toxic substances from the body.